1. Annals of Internal Medicine. Information for authors: General statistical guidance (section 4: Measures of effect and risk). https://www.acpjournals.org/journal/aim/authors/statistical-guidance (accessed July 31, 2023)
2. Cobos-Carbo, A. and Augustovski, F. (2011). CONSORT 2010 Declaration: updated guideline for reporting parallel group randomised trials. Medicina Clinica, 137, 213-215.
3. Connolly, S.J., Karthikeyan, G., Ntsekhe, M., Haileamlak, A., El Sayed, A., El Ghamrawy, A. et al. (2022). Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. The New England Journal of Medicine, 387, 978-988.
4. Cox, D.R. (1972). Regression models and life-tables. Journal of the Royal Statistical Society. Series B, Statistical Methodology, 34, 187-202.
5. Guimarães, H.P., Lopes, R.D., de Barros E Silva, P.G.M., Liporace, I.L., Sampaio, R.O., Tarasoutchi, F. et al. (2020). Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. The New England Journal of Medicine, 383, 2117-2126.